Form 4: CEO Rick Winningham Disposes of TBPH Shares for Taxes

Theravance Biopharma CEO Rick Winningham withheld 20,038 shares to satisfy tax obligations related to restricted stock unit vesting.

Summary

• CEO Rick Winningham disposed of 20,038 ordinary shares of Theravance Biopharma, Inc. (TBPH).
• The transaction occurred on May 20, 2026, at a price of $16.55 per share.
• The disposal was a mandatory tax withholding event related to the vesting of restricted stock units (RSUs).
• Following this transaction, the CEO maintains direct ownership of 1,631,056 shares, with additional indirect holdings via a trust and as a custodian.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax obligation rather than a strategic shift or market-driven divestment.

Positives

• The transaction was a routine tax withholding event rather than an open-market sale, indicating no change in the CEO's long-term confidence in the company.

Negatives

• Reduction in the total number of shares held directly by the CEO.

Risks

• None identified; this is a standard administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The filing notes that the share withholding transaction was with the issuer and did not involve an open market transaction.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for executives in the biopharmaceutical sector to cover tax liabilities upon the vesting of equity-based compensation.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity compensation management.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax withholding event.

Next Steps

• None mentioned.

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Executive Compensation, Tax Withholding